Johnson & Johnson (JNJ)vsZevra Therapeutics Inc. (ZVRA)
JNJ
Johnson & Johnson
$272.65
-1.45%
HEALTHCARE · Cap: $657.68B
ZVRA
Zevra Therapeutics Inc.
$10.53
-5.73%
HEALTHCARE · Cap: $597.10M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 72902% more annual revenue ($99.33B vs $136.07M). ZVRA leads profitability with a 42.8% profit margin vs 16.2%. JNJ appears more attractively valued with a PEG of 3.07. ZVRA earns a higher WallStSmart Score of 66/100 (B-).
JNJ
Buy54
out of 100
Grade: C-
ZVRA
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.3%
Fair Value
$144.28
Current Price
$272.65
$128.37 premium
Margin of Safety
+64.0%
Fair Value
$23.52
Current Price
$10.53
$12.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Attractively priced relative to earnings
Keeps 43 of every $100 in revenue as profit
Strong operational efficiency at 42.3%
Revenue surging 53.3% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 27 in profit
Areas to Watch
Trading at 8.0x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Expensive relative to growth rate
Earnings declined 88.4%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : ZVRA
The strongest argument for ZVRA centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 42.8% and operating margin at 42.3%. Revenue growth of 53.3% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : ZVRA
The primary concerns for ZVRA are Market Cap, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while ZVRA is a growth play — different risk/reward profiles.
ZVRA carries more volatility with a beta of 0.98 — expect wider price swings.
ZVRA is growing revenue faster at 53.3% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
ZVRA scores higher overall (66/100 vs 54/100), backed by strong 42.8% margins and 53.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?